Adiponectin
The adiponectin test measures serum concentration of an adipocyte-derived hormone that uniquely falls in obesity and insulin resistance. Low adiponectin is a biomarker of metabolic dysfunction, correlating with visceral adiposity, type 2 diabetes, and cardiovascular risk, and is used to refine metabolic risk stratification and monitor insulin-sensitising interventions.
1
Biomarkers
Blood (serum)
Sample
3–7 business days
Turnaround
Yes
Fasting
What is the Adiponectin test?
The Adiponectin test measures the serum concentration of an insulin-sensitising adipokine that uniquely falls in obesity and metabolic dysfunction. Practitioners order it not as a first-line diagnostic tool but as an adjunct to conventional metabolic markers when seeking to understand why a patient with central obesity has disproportionate metabolic or cardiovascular risk, or when standard measures such as HbA1c and lipids do not fully explain the clinical picture. Adiponectin sits at the intersection of adipose biology, insulin resistance, and inflammation. A low value in the setting of normal or borderline glucose and lipids can unmask early metabolic risk and justify intensified lifestyle or pharmacological intervention. Serial testing helps track the response to weight loss, exercise, thiazolidinedione therapy, or omega-3 supplementation, all of which have been shown to raise adiponectin. The test is particularly valuable in patients with metabolic syndrome, polycystic ovary syndrome, non-alcoholic fatty liver disease, or a family history of premature cardiovascular disease, where conventional risk scores may underestimate true risk.
What does the Adiponectin test measure?
Adiponectin is a 244-amino-acid peptide hormone secreted exclusively by adipocytes, circulating in several oligomeric forms — trimeric (low molecular weight), hexameric (medium), and a high-molecular-weight (HMW) multimer that is thought to be the most metabolically active. Unlike most adipokines, adiponectin secretion is inversely related to adipose tissue mass, so concentrations fall in obesity and insulin resistance. It acts through two G-protein-coupled receptors, AdipoR1 in skeletal muscle and AdipoR2 in the liver, to activate AMP-activated protein kinase and peroxisome proliferator-activated receptor alpha pathways, enhancing fatty-acid oxidation, glucose uptake, and insulin sensitivity while suppressing hepatic gluconeogenesis and inflammation.
Low adiponectin is a biomarker of metabolic dysfunction and insulin resistance, correlating with visceral adiposity, type 2 diabetes risk, and cardiovascular disease. It is not a routine diagnostic test but a research-validated marker that practitioners use to refine metabolic risk stratification, monitor interventions aimed at improving insulin sensitivity, and assess residual cardiometabolic risk in patients with central obesity or metabolic syndrome despite acceptable conventional lipid and glucose measures.
Why is the Adiponectin test ordered?
- Metabolic risk stratification in patients with central obesity, metabolic syndrome, or insulin resistance who have borderline conventional markers
- Evaluation of residual cardiometabolic risk in patients with controlled glucose and lipids but persistent visceral adiposity
- Monitoring response to weight-loss interventions, structured exercise programmes, or insulin-sensitising therapies such as thiazolidinediones
- Assessment of women with polycystic ovary syndrome to quantify metabolic dysfunction beyond androgen and ovulatory indices
- Investigation of patients with non-alcoholic fatty liver disease to gauge the severity of underlying metabolic disturbance
- Risk assessment in individuals with a strong family history of premature cardiovascular disease or type 2 diabetes, particularly when phenotypically lean but metabolically unhealthy
- Research and precision-medicine protocols exploring adipokine biology, inflammageing, or individualised metabolic interventions
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
Yes
Collection method
Venipuncture at patient service centre
Turnaround
3–7 business days
Collection notes
Phlebotomy at the processing laboratory's draw site (Quest, LabCorp, Boston Heart Diagnostics, or Access Medical Laboratories, depending on routing). Fasting ≥8 hours is preferred to minimise postprandial variability. Note the performing laboratory and assay platform for serial comparability, as adiponectin assays differ in oligomer specificity and reference intervals.
Specimen requirements
Minimum 0.5 mL serum. Separate from cells within 2 hours; adiponectin is stable refrigerated for up to 7 days and freeze–thaw stable. Some laboratories specify frozen transport for send-out assays; confirm with the routing lab.
What can affect Adiponectin results?
Women have higher circulating adiponectin than men, and oestrogen appears to upregulate its secretion. Pregnancy, oral contraceptives, and hormone-replacement therapy can all influence concentrations, so interpret sex-specific reference intervals carefully.
Adiponectin shows modest diurnal rhythm and is relatively stable postprandially, but fasting samples are preferred to minimise variability and ensure comparability with published reference data.
Pioglitazone and rosiglitazone are potent stimulators of adiponectin secretion, often doubling circulating concentrations. A rise during therapy is mechanistically linked to improved insulin sensitivity.
Loss of visceral adipose mass and improvement in insulin sensitivity increase adiponectin, making it a useful biomarker for tracking metabolic benefit from lifestyle intervention.
Adiponectin is partially cleared by the kidney, so reduced glomerular filtration raises circulating levels. Paradoxically high adiponectin in advanced CKD may not reflect improved metabolic health and must be interpreted in the renal context.
Total adiponectin assays measure all oligomeric forms, while some platforms quantify high-molecular-weight adiponectin specifically. Results are not interchangeable, and serial monitoring should use the same assay and laboratory.
What do Adiponectin results mean?
Elevated
High adiponectin generally reflects favourable metabolic status — lower visceral fat, better insulin sensitivity, and reduced cardiovascular risk. Paradoxically high concentrations can occur in chronic kidney disease due to reduced clearance, in heart failure, and in some cachectic states; correlate with renal function and clinical context.
Normal
Concentrations within the reference interval suggest intact adipose endocrine function and reasonable insulin sensitivity, though interpretation must account for sex, obesity status, and the assay used. Normal adiponectin does not exclude metabolic risk if other markers are abnormal.
Reduced
Low adiponectin is strongly associated with visceral obesity, insulin resistance, type 2 diabetes, metabolic syndrome, and increased cardiovascular risk. It is also reduced in polycystic ovary syndrome and non-alcoholic fatty liver disease. A low value in the setting of normal glucose and lipids flags early metabolic dysfunction and residual risk.
Note: Adiponectin is not a stand-alone diagnostic test. It refines risk stratification and tracks intervention response but must be read alongside glucose, HbA1c, lipids, inflammatory markers, and anthropometric data. Reference intervals and optimal thresholds are assay- and sex-dependent, and results from different laboratories or platforms should not be assumed interchangeable.
Frequently asked questions
Adiponectin is a hormone secreted by fat cells that enhances insulin sensitivity and fatty-acid oxidation. Unlike other adipokines, its production decreases as fat mass increases, particularly visceral fat, making low adiponectin a marker of metabolic dysfunction.
How to access the Adiponectin test
The Adiponectin reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Yamauchi T, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. (2002)
- Hotta K, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. (2000)
- Pischon T, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. (2004)
- Spranger J, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. (2003)
- Kadowaki T, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. (2006)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.